Attached files
| file | filename |
|---|---|
| EX-10.1 - EX-10.1 - Allergan plc | d230870dex101.htm |
| 8-K - FORM 8-K - Allergan plc | d230870d8k.htm |
Exhibit 99.1
The following tables represent the segment contribution of Allergan plc for the three months ended June 30, 2016, March 31, 2016, December 31, 2015, September 30, 2015, June 30, 2015 and March 31, 2015:
| Three Months Ended June 30, 2016 | ||||||||||||||||
| (unaudited; $ in millions) |
US Specialized Therapeutics |
US General Medicine |
International | TOTAL | ||||||||||||
| Eye Care |
$ | 636.1 | $ | — | $ | 318.7 | $ | 954.8 | ||||||||
| Medical Aesthetics |
419.8 | — | 284.1 | 703.9 | ||||||||||||
| Gastroenterology |
— | 442.0 | — | 442.0 | ||||||||||||
| Neurosciences & Urology |
326.3 | — | — | 326.3 | ||||||||||||
| CNS |
— | 317.5 | — | 317.5 | ||||||||||||
| Women’s Health |
— | 296.1 | — | 296.1 | ||||||||||||
| Medical Dermatology |
97.1 | — | — | 97.1 | ||||||||||||
| Anti - Infectives |
— | 63.1 | — | 63.1 | ||||||||||||
| Other |
9.6 | 330.4 | 154.2 | 494.2 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net revenue |
$ | 1,488.9 | $ | 1,449.1 | $ | 757.0 | $ | 3,695.0 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Cost of sales |
75.1 | 214.9 | 115.0 | 405.0 | ||||||||||||
| Selling & marketing |
287.8 | 332.7 | 207.2 | 827.7 | ||||||||||||
| General & administrative |
46.0 | 43.7 | 30.9 | 120.6 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Segment contribution |
$ | 1,080.0 | $ | 857.8 | $ | 403.9 | $ | 2,341.7 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Contribution margin |
72.5 | % | 59.2 | % | 53.4 | % | 63.4 | % | ||||||||
| Corporate |
308.4 | |||||||||||||||
| Research and development |
636.5 | |||||||||||||||
| Amortization |
1,633.1 | |||||||||||||||
| In-process research and development impairments |
268.9 | |||||||||||||||
| Asset sales & impairments, net |
(17.6 | ) | ||||||||||||||
|
|
|
|||||||||||||||
| Operating income/(loss) |
(487.6 | ) | ||||||||||||||
|
|
|
|||||||||||||||
| Operating margin |
-13.2 | % | ||||||||||||||
| Three Months Ended March 31, 2016 | ||||||||||||||||
| (unaudited; $ in millions) |
US Specialized Therapeutics |
US General Medicine |
International | TOTAL | ||||||||||||
| Eye Care |
$ | 533.0 | $ | — | $ | 291.5 | $ | 824.5 | ||||||||
| Medical Aesthetics |
373.9 | — | 244.9 | 618.8 | ||||||||||||
| Gastroenterology |
— | 403.6 | — | 403.6 | ||||||||||||
| Neurosciences & Urology |
306.8 | — | — | 306.8 | ||||||||||||
| CNS |
— | 321.6 | — | 321.6 | ||||||||||||
| Women’s Health |
— | 263.7 | — | 263.7 | ||||||||||||
| Medical Dermatology |
69.0 | — | — | 69.0 | ||||||||||||
| Anti - Infectives |
— | 51.5 | — | 51.5 | ||||||||||||
| Other |
16.0 | 413.3 | 136.9 | 566.2 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net revenue |
$ | 1,298.7 | $ | 1,453.7 | $ | 673.3 | $ | 3,425.7 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Cost of sales |
70.7 | 219.6 | 99.2 | 389.5 | ||||||||||||
| Selling & marketing |
264.6 | 277.3 | 187.3 | 729.2 | ||||||||||||
| General & administrative |
39.2 | 42.2 | 27.6 | 109.0 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Segment contribution |
$ | 924.2 | $ | 914.6 | $ | 359.2 | $ | 2,198.0 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Contribution margin |
71.2 | % | 62.9 | % | 53.3 | % | 64.2 | % | ||||||||
| Corporate |
372.4 | |||||||||||||||
| Research and development |
403.1 | |||||||||||||||
| Amortization |
1,589.7 | |||||||||||||||
| In-process research and development impairments |
6.0 | |||||||||||||||
| Asset sales & impairments, net |
(1.7 | ) | ||||||||||||||
|
|
|
|||||||||||||||
| Operating income/(loss) |
(171.5 | ) | ||||||||||||||
|
|
|
|||||||||||||||
| Operating margin |
-5.0 | % | ||||||||||||||
| Three Months Ended December 31, 2015 | ||||||||||||||||
| (unaudited; $ in millions) |
US Specialized Therapeutics |
US General Medicine |
International | TOTAL | ||||||||||||
| Eye Care |
$ | 618.1 | $ | — | $ | 295.0 | $ | 913.1 | ||||||||
| Medical Aesthetics |
383.6 | — | 246.4 | 630.0 | ||||||||||||
| Gastroenterology |
— | 436.9 | — | 436.9 | ||||||||||||
| Neurosciences & Urology |
301.7 | — | — | 301.7 | ||||||||||||
| CNS |
— | 356.0 | — | 356.0 | ||||||||||||
| Women’s Health |
— | 281.3 | — | 281.3 | ||||||||||||
| Medical Dermatology |
106.5 | — | — | 106.5 | ||||||||||||
| Anti - Infectives |
— | 50.5 | — | 50.5 | ||||||||||||
| Other |
10.3 | 410.0 | 149.5 | 569.8 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net revenue |
$ | 1,420.2 | $ | 1,534.7 | $ | 690.9 | $ | 3,645.8 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Cost of sales |
75.6 | 235.5 | 107.1 | 418.2 | ||||||||||||
| Selling & marketing |
247.8 | 277.6 | 175.0 | 700.4 | ||||||||||||
| General & administrative |
22.2 | 16.5 | 31.9 | 70.6 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Segment contribution |
$ | 1,074.6 | $ | 1,005.1 | $ | 376.9 | $ | 2,456.6 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Contribution margin |
75.7 | % | 65.5 | % | 54.6 | % | 67.4 | % | ||||||||
| Corporate |
727.8 | |||||||||||||||
| Research and development |
430.6 | |||||||||||||||
| Amortization |
1,584.9 | |||||||||||||||
| In-process research and development impairments |
14.0 | |||||||||||||||
| Asset sales & impairments, net |
268.9 | |||||||||||||||
|
|
|
|||||||||||||||
| Operating income/(loss) |
(569.6 | ) | ||||||||||||||
|
|
|
|||||||||||||||
| Operating margin |
-15.6 | % | ||||||||||||||
| Three Months Ended September 30, 2015 | ||||||||||||||||
| (unaudited; $ in millions) |
US Specialized Therapeutics |
US General Medicine |
International | TOTAL | ||||||||||||
| Eye Care |
$ | 539.9 | $ | — | $ | 281.5 | $ | 821.4 | ||||||||
| Medical Aesthetics |
340.1 | — | 214.8 | 554.9 | ||||||||||||
| Gastroenterology |
— | 398.6 | — | 398.6 | ||||||||||||
| Neurosciences & Urology |
291.4 | — | — | 291.4 | ||||||||||||
| CNS |
— | 406.7 | — | 406.7 | ||||||||||||
| Women’s Health |
— | 268.0 | — | 268.0 | ||||||||||||
| Medical Dermatology |
107.8 | — | — | 107.8 | ||||||||||||
| Anti - Infectives |
— | 52.3 | — | 52.3 | ||||||||||||
| Other |
17.4 | 426.4 | 164.3 | 608.1 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net revenue |
$ | 1,296.6 | $ | 1,552.0 | $ | 660.6 | $ | 3,509.2 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Cost of sales |
71.6 | 227.5 | 108.3 | 407.4 | ||||||||||||
| Selling & marketing |
236.2 | 262.8 | 155.8 | 654.8 | ||||||||||||
| General & administrative |
17.2 | 17.5 | 33.3 | 68.0 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Segment contribution |
$ | 971.6 | $ | 1,044.2 | $ | 363.2 | $ | 2,379.0 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Contribution margin |
74.9 | % | 67.3 | % | 55.0 | % | 67.8 | % | ||||||||
| Corporate |
642.6 | |||||||||||||||
| Research and development |
1,260.5 | |||||||||||||||
| Amortization |
1,557.8 | |||||||||||||||
| In-process research and development impairments |
300.0 | |||||||||||||||
| Asset sales & impairments, net |
(4.4 | ) | ||||||||||||||
|
|
|
|||||||||||||||
| Operating income/(loss) |
(1,377.5 | ) | ||||||||||||||
|
|
|
|||||||||||||||
| Operating margin |
-39.3 | % | ||||||||||||||
| Three Months Ended June 30, 2015 | ||||||||||||||||
| (unaudited; $ in millions) |
US Specialized Therapeutics |
US General Medicine |
International | TOTAL | ||||||||||||
| Eye Care |
$ | 578.6 | $ | — | $ | 301.7 | $ | 880.3 | ||||||||
| Medical Aesthetics |
366.2 | — | 262.2 | 628.4 | ||||||||||||
| Gastroenterology |
— | 373.2 | — | 373.2 | ||||||||||||
| Neurosciences & Urology |
277.7 | — | — | 277.7 | ||||||||||||
| CNS |
— | 560.8 | — | 560.8 | ||||||||||||
| Women’s Health |
— | 219.4 | — | 219.4 | ||||||||||||
| Medical Dermatology |
120.7 | — | — | 120.7 | ||||||||||||
| Anti - Infectives |
— | 44.1 | — | 44.1 | ||||||||||||
| Other |
4.5 | 410.5 | 153.2 | 568.2 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net revenue |
$ | 1,347.7 | $ | 1,608.0 | $ | 717.1 | $ | 3,672.8 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Cost of sales |
74.4 | 238.0 | 111.8 | 424.2 | ||||||||||||
| Selling & marketing |
247.8 | 309.2 | 196.1 | 753.1 | ||||||||||||
| General & administrative |
20.9 | 18.1 | 35.0 | 74.0 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Segment contribution |
$ | 1,004.6 | $ | 1,042.7 | $ | 374.2 | $ | 2,421.5 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Contribution margin |
74.5 | % | 64.8 | % | 52.2 | % | 65.9 | % | ||||||||
| Corporate |
831.7 | |||||||||||||||
| Research and development |
349.7 | |||||||||||||||
| Amortization |
1,515.7 | |||||||||||||||
| In-process research and development impairments |
197.6 | |||||||||||||||
| Asset sales & impairments, net |
2.9 | |||||||||||||||
|
|
|
|||||||||||||||
| Operating income/(loss) |
(476.1 | ) | ||||||||||||||
|
|
|
|||||||||||||||
| Operating margin |
-13.0 | % | ||||||||||||||
| Three Months Ended March 31, 2015 | ||||||||||||||||
| (unaudited; $ in millions) |
US Specialized Therapeutics |
US General Medicine |
International | TOTAL | ||||||||||||
| Eye Care |
$ | 94.7 | $ | — | $ | 40.5 | $ | 135.2 | ||||||||
| Medical Aesthetics |
55.1 | — | 32.9 | 88.0 | ||||||||||||
| Gastroenterology |
— | 366.6 | — | 366.6 | ||||||||||||
| Neurosciences & Urology |
68.1 | — | — | 68.1 | ||||||||||||
| CNS |
— | 517.6 | — | 517.6 | ||||||||||||
| Women’s Health |
— | 229.3 | — | 229.3 | ||||||||||||
| Medical Dermatology |
20.9 | — | — | 20.9 | ||||||||||||
| Anti - Infectives |
— | 41.9 | — | 41.9 | ||||||||||||
| Other |
6.5 | 488.3 | 45.3 | 540.1 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net revenue |
$ | 245.3 | $ | 1,643.7 | $ | 118.7 | $ | 2,007.7 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Cost of sales |
14.2 | 208.5 | 23.7 | 246.4 | ||||||||||||
| Selling & marketing |
41.0 | 345.1 | 42.3 | 428.4 | ||||||||||||
| General & administrative |
8.0 | 53.2 | 7.4 | 68.6 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Segment contribution |
$ | 182.1 | $ | 1,036.9 | $ | 45.3 | $ | 1,264.3 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Contribution margin |
74.2 | % | 63.1 | % | 38.2 | % | 63.0 | % | ||||||||
| Corporate |
864.6 | |||||||||||||||
| Research and development |
317.7 | |||||||||||||||
| Amortization |
785.4 | |||||||||||||||
| In-process research and development impairments |
— | |||||||||||||||
| Asset sales & impairments, net |
4.6 | |||||||||||||||
|
|
|
|||||||||||||||
| Operating income/(loss) |
(708.0 | ) | ||||||||||||||
|
|
|
|||||||||||||||
| Operating margin |
-35.3 | % | ||||||||||||||